Aravax Is A Clinical Stage Biotechnology Company Based In Melbourneaustraliafounded In May 2015The Company Focuses On Developing Innovative Treatments For Peanut And Other Food Allergiesutilizing Intellectual Property From Alfred Health And Monash Universityaravax S Lead Productpvx108Is A Peptide Immunotherapy Currently In Phase 2 Clinical Trialsaimed At Helping Adolescents And Children Tolerate Allergens Without Triggering Allergic Reactions The Company Has Expanded Its Operations Internationallyestablishing A Pharmaceutical Development Base At The Oxford Science Park In The Ukthis Subsidiary Is Dedicated To Developing Commercial Manufacturing Processes For Its Peptide Drug Substancesaravax Has Also Secured Significant Investment Through A Series B Funding Roundwhich Includes Partnerships With Notable Investors Like Novartis Venture Fund And Breakthrough Victoriathese Efforts Support The Ongoing Development Of Pvx108 And The Company S Broader Product Pipeline
No conferences found for this company.
| Company Name | Aravax Pty Ltd |
| Country |
Australia
|
| Address | N/A |
| Telephone | N/A |
| N/A |
